99mTc-FAPI Dimeric Probe for Higher Tumor Uptake and Contrast
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic FAP probes based on 99mTc-SPECT have relatively low tumor uptake rates and imaging contrast, limiting their effectiveness in tumor diagnosis.
Innovation Solution
Development of a dimeric compound targeting FAP with a novel piperazinyl quinolone-based skeleton, labeled with technetium-99m, utilizing specific linkers and a nuclide chelating group to enhance tumor uptake and imaging contrast.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic FAP probes based on 99mTc-SPECT are used, then tumor imaging is achieved, but tumor uptake rate and imaging contrast are relatively low
Solution Approach 1:
The patent divides the probe structure into distinct functional segments: a targeting ligand portion that binds to FAP receptors on tumor cells, a radioisotope chelating portion that binds to 99mTc, and a linker connecting them. This segmentation allows optimization of each component independently to enhance both tumor uptake and imaging contrast while reducing background signal in non-target organs.
Solution Approach 2:
The patent modifies key parameters of the probe including the chemical structure of the targeting ligand (using piperazinyl quinolone derivatives), the linker properties (length, composition, and type), and the chelating group configuration. These parameter changes optimize the probe's pharmacokinetic properties, resulting in improved tumor uptake rate and imaging contrast ratio.
2Quantity of substance
If a dimeric compound structure is adopted, then tumor uptake rate and retention are improved, but molecular complexity increases
Solution Approach 1:
The patent merges two identical or similar probe units into a dimeric structure through a linker, creating a bivalent targeting agent. This merging doubles the number of targeting sites, significantly enhancing tumor uptake rate and retention through increased binding avidity, while the modular design keeps the complexity manageable.
Solution Approach 2:
The dimeric probe represents a composite molecular structure combining organic ligand components with a metal radioisotope (99mTc) coordinated to chelating groups. This composite approach integrates the high affinity of organic FAP binders with the detectability of gamma-emitting 99mTc, achieving superior imaging performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dimeric compound achieves higher tumor uptake rates, faster tumor targeting, and improved retention, with reduced physiological uptake in non-target organs, offering better pharmacokinetic properties for clinical applications.
Implementation Method 1
Q is a hydrogen atom or is used as a nuclide chelating group moiety, and is selected from any group that can be chelate-coordinated with technetium-99mTc
Data Source
AI summary
The present disclosure discloses a brand-new skeleton 99mTc-FAPI diagnostic probe and use thereof in the preparation of a drug or a reagent for diagnosing tumors, wherein the structural formula of a dimeric compound targeting FAP is shown by following formula. Compared with conventional FAP inhibitor radiopharmaceuticals, technetium-99m-labeled novel skeleton FAP inhibitor dimeric compound has a very high tumor uptake rate, high contrast between tumor and background and good in vivo biodistribution.